Fosun Pharma Subsidiary Henlius Enters Licensing Agreement with Eisai for Serplulimab in Japan

Fosun Pharmaceutical: Its subsidiary Shanghai Henlius Biotech, Inc. has signed a "License Agreement" with Eisai Co., Ltd. Under the agreement, Shanghai Henlius Biotech, Inc. grants Eisai the rights to develop, manufacture, and commercialize Serplulimab Injection within the licensed territory (i.e., Japan) and field (i.e., for oncology indications treatment). According to the terms, Eisai shall pay Shanghai Henlius Biotech, Inc. an upfront fee and regulatory milestone payments of up to 155 million USD, which are non-refundable.